Decitabine Injection
Brand names: Decitabine
Category: Oncology
FDA status: To Be Discontinued · Last FDA update: Feb 20, 2026 · First posted: Feb 20, 2026 · 1 manufacturers, 2 listed presentations
As of Feb 20, 2026, the FDA lists Decitabine Injection as being discontinued. Of 2 manufacturer presentations, 2 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Decitabine, Injection, 50 mg (NDC 68001-573-41) NDC 68001-573-41 |
Ingenus Pharmaceuticals LLC | Not specified | Labeler: BluePoint Laboratories; Discontinuation of the manufacture of the drug |
| Decitabine, Injection, 50 mg (NDC 50742-430-01) NDC 50742-430-01 |
Ingenus Pharmaceuticals LLC | Not specified | Discontinuation of the manufacture of the drug |
Related medications in shortage
Other Oncology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Decitabine Injection (FDA data as of Feb 20, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Decitabine Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/decitabine-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).